NeuroSense Therapeutics Ltd. (NRSNW)
NRSNW Stock Price Chart
Explore NeuroSense Therapeutics Ltd. interactive price chart. Choose custom timeframes to analyze NRSNW price movements and trends.
NRSNW Company Profile
Discover essential business fundamentals and corporate details for NeuroSense Therapeutics Ltd. (NRSNW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
—
Employees
17.00
Website
https://www.neurosense-tx.comCEO
Alon Ben-Noon
Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NRSNW Financial Timeline
Browse a chronological timeline of NeuroSense Therapeutics Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 1 Aug 2025
EPS came in at -$0.14 surpassing the estimated -$0.22 by +38.14%.
Earnings released on 28 May 2025
EPS came in at -$0.11 falling short of the estimated -$0.10 by -4.80%.
NRSNW Stock Performance
Access detailed NRSNW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.